Blonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.
Features and Benefits
This compound was developed by Dainippon Sumitomo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Psychiatry and clinical neurosciences, 66(2), 146-152 (2012-02-23)
Blonanserin is a second-generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti-5-HT(2A) activity/anti-D₂ activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing. The subjects were 29 outpatients with schizophrenia. We assessed
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 903, 46-52 (2012-07-24)
Blonanserin is a novel atypical antipsychotic with highly selective receptor antagonist activity to dopamine D₂ and 5-HT(2A). N-desethyl blonanserin (blonanserin C) is its major active metabolite in human plasma. Herein we report a new highly sensitive, selective, and rapid liquid
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 26(10), 1099-1102 (2010-10-19)
A rapid and sensitive method for analysis of blonanserin in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry is presented. After pretreatment of a plasma sample by solid-phase extraction, blonanserin was analyzed by the system with a C(18) column. This
We offer many products related to serotonin receptors for your research needs.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
